1. Home
  2. BLRX vs UCL Comparison

BLRX vs UCL Comparison

Compare BLRX & UCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLRX
  • UCL
  • Stock Information
  • Founded
  • BLRX 2003
  • UCL 2014
  • Country
  • BLRX Israel
  • UCL Hong Kong
  • Employees
  • BLRX N/A
  • UCL N/A
  • Industry
  • BLRX Biotechnology: Pharmaceutical Preparations
  • UCL Telecommunications Equipment
  • Sector
  • BLRX Health Care
  • UCL Consumer Discretionary
  • Exchange
  • BLRX Nasdaq
  • UCL Nasdaq
  • Market Cap
  • BLRX 36.0M
  • UCL 48.7M
  • IPO Year
  • BLRX 2011
  • UCL 2020
  • Fundamental
  • Price
  • BLRX $0.20
  • UCL $2.13
  • Analyst Decision
  • BLRX Strong Buy
  • UCL
  • Analyst Count
  • BLRX 2
  • UCL 0
  • Target Price
  • BLRX $5.50
  • UCL N/A
  • AVG Volume (30 Days)
  • BLRX 1.7M
  • UCL 374.6K
  • Earning Date
  • BLRX 11-25-2024
  • UCL 11-26-2024
  • Dividend Yield
  • BLRX N/A
  • UCL N/A
  • EPS Growth
  • BLRX N/A
  • UCL 169.91
  • EPS
  • BLRX N/A
  • UCL 0.11
  • Revenue
  • BLRX $21,991,000.00
  • UCL $87,405,000.00
  • Revenue This Year
  • BLRX N/A
  • UCL $11.23
  • Revenue Next Year
  • BLRX N/A
  • UCL $27.52
  • P/E Ratio
  • BLRX N/A
  • UCL $18.65
  • Revenue Growth
  • BLRX N/A
  • UCL 4.73
  • 52 Week Low
  • BLRX $0.19
  • UCL $0.97
  • 52 Week High
  • BLRX $1.68
  • UCL $3.30
  • Technical
  • Relative Strength Index (RSI)
  • BLRX 25.94
  • UCL 62.21
  • Support Level
  • BLRX $0.23
  • UCL $1.41
  • Resistance Level
  • BLRX $0.56
  • UCL $3.30
  • Average True Range (ATR)
  • BLRX 0.03
  • UCL 0.39
  • MACD
  • BLRX 0.00
  • UCL 0.11
  • Stochastic Oscillator
  • BLRX 11.82
  • UCL 45.33

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

About UCL uCloudlink Group Inc.

Ucloudlink Group Inc provides mobile data connectivity and portable WiFi services. The business operates under uCloudlink 1.0, which focuses on cross-border travelers that need mobile data connectivity services across different countries. Under uCloudlink 2.0, provides mobile data connectivity services to local users across different MNOs in a single country. It generates revenue from the provision of data connectivity services, and the sales of terminals and sales of data related products.

Share on Social Networks: